You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Targeted Pet Imaging

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aldosterone-Producing Adenoma Trial (CXCR4)

Not yet recruiting
  • Aldosterone-Producing Adenoma
  • CXCR4
  • (no location specified)
Apr 20, 2023

Interstitial Lung Disease Trial in Boston ([68Ga]CBP8, Dotarem)

Recruiting
  • Interstitial Lung Disease
  • Boston, Massachusetts
    Massachusetts General Hospital
Aug 22, 2022

Prostate Cancer Trial in Bala-Cynwyd (rhPSMA-7.3 (18F))

Not yet recruiting
  • Prostate Cancer
  • rhPSMA-7.3 (18F)
  • Bala-Cynwyd, Pennsylvania
    MidLantic Urology
Mar 22, 2023

Schwannomas, Malignant Tumors Trial in Baltimore (18F-DCFPyL Injection)

Completed
  • Schwannomas
  • Malignant Tumors
  • 18F-DCFPyL Injection
  • Baltimore, Maryland
    Johns Hopkins University
Jan 9, 2023

Meningioma Trial in New York (Ga-68- DOTATATE, Ga-68-DOTATOC)

Recruiting
  • Meningioma
  • New York, New York
    Weill Cornell Medical College of Cornell University
Apr 10, 2022

Tumor, Solid, Positron-Emission Tomography Trial in Xiamen (18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT)

Recruiting
  • Tumor, Solid
  • Positron-Emission Tomography
  • 18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Sep 16, 2022

Gastrointestinal Cancer Trial in Beijing (Intravenous injection of 68Ga-PMD22)

Recruiting
  • Gastrointestinal Cancer
  • Intravenous injection of 68Ga-PMD22
  • Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Jun 30, 2023

Prostate Carcinoma Trial in Chicago (Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol)

Not yet recruiting
  • Prostate Carcinoma
  • Fluorine F 18 DCFPyL
  • +6 more
  • Chicago, Illinois
    Northwestern University
Aug 2, 2022

CXCR4, PET/CT, Hematological Malignancy Trial in Wuhan (68Ga-pentixafor, PET/CT)

Not yet recruiting
  • CXCR4
  • +2 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Feb 15, 2022

Breast Cancer Trial in Birmingham ([89Zr]-Df-Trastuzumab, PET/MRI Imaging)

Recruiting
  • Breast Cancer
  • Birmingham, Alabama
    The Kirklin Clinic
Feb 1, 2022

Psoriatic Arthritis Trial in Beijing (68Ga-FAPI)

Recruiting
  • Psoriatic Arthritis
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jan 7, 2023

Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)

Recruiting
  • Multiple Myeloma
  • 89Zr-daratumumab PET/CT
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
Aug 1, 2022

Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal Trial in Rochester ([203Pb]VMT01, [68Ga]VMT02)

Recruiting
  • Melanoma (Skin)
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic
Aug 5, 2022

Cancer, Non Small Cell Lung Cancer Trial in Salt Lake City (PET Imaging, Erlotinib, Bevacizumab)

Completed
  • Cancer
  • Non Small Cell Lung Cancer
  • PET Imaging
  • +2 more
  • Salt Lake City, Utah
    Huntsman Cancer Institute
Dec 16, 2021

HER2-positive Breast Cancer Trial in Birmingham ([18F]-FDG)

Recruiting
  • HER2-positive Breast Cancer
  • Birmingham, Alabama
    The University of Alabama at Birmingham
Jan 31, 2022

Abdominal Aortic Aneurysm (AAA) Trial in Saint Louis (Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of

Terminated
  • Abdominal Aortic Aneurysm (AAA)
  • Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i
  • AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 9, 2022

Aortic Aneurysm, Abdominal, Carotid Atherosclerosis Trial in Stanford (drug, device, procedure)

Withdrawn
  • Aortic Aneurysm, Abdominal
  • Carotid Atherosclerosis
  • Stanford, California
    Stanford University
May 19, 2021

Breast Cancer Metastases, HER2 Positive Breast Trial in New York (89Zr-trastuzumab, PET/CT scan, 89Zr-pertuzumab)

Completed
Has Results
  • Breast Cancer Metastases
  • HER2 Positive Breast
  • 89Zr-trastuzumab
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 25, 2021

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023

Prostate Cancer Trial in Baltimore (18F-DCFPyL Injection)

Withdrawn
  • Prostate Cancer
  • 18F-DCFPyL Injection
  • Baltimore, Maryland
    Johns Hopkins University
Dec 14, 2021

Multi-layer Data to Improve Diagnosis, Predict Therapy

Recruiting
  • High Grade Ovarian Serous Adenocarcinoma
  • WGS and RNA sequencing
  • +2 more
  • Turku, Finland
    Turku University Hospital
Apr 26, 2022

Integrin avß6-targeted PET in Malignant Tumors

Recruiting
  • Malignant Neoplasm
  • +2 more
    • Wuhan, Hubei, China
      Zhongnan Hospital of Wuhan University
    Apr 18, 2023

    Estrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 Trial in Seattle (procedure, drug,

    Terminated
    Has Results
    • Estrogen Receptor Positive
    • +2 more
    • Computed Tomography
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jun 28, 2021

    PET/CT Characterization of Treatment Resistance

    Recruiting
    • Prostate Cancer
    • F-fluorodeoxyglucose positron emission tomography (FDG PET)
    • prostate-specific membrane antigen positron emission tomography (PSMA PET)
    • Madison, Wisconsin
      University of Wisconsin
    Jan 24, 2023

    Rectal Cancer Trial in Wuhan (68Ga-FAPI-04, 18F-FDG)

    Recruiting
    • Rectal Cancer
    • Wuhan, Hubei, China
      China, Hubei Province
    Aug 11, 2023